news

Exscientia to collaborate with Sanofi for EUR250mil multiple-product development

Exscientia has agreed a strategic research collaboration, and licence option agreement with Sanofi in the high-interest area of metabolic disease.

Exscientia announces collaboration for a multiple-product development and licence option agreement with Sanofi

Delivery of new therapies for metabolic disease (such as diabetes) is hampered by a paucity of single targets that are amenable to drug discovery. To address this challenge, Exscientia will apply its unique platform to identify and validate combinations of drug targets* that could work synergistically and be amenable to Exscientia’s bispecific-small-molecule design strategy – where a small molecule is designed to be compatible with two distinct drug targets.

Starting with over a thousand disease-relevant target combinations, Exscientia will triage opportunities and prioritise those with promising bispecific binding potential. Target pairs fulfilling these initial tractability criteria will pass through to Exscientia’s lead-finding platform in order to generate bispecific-small-molecule compounds that can further validate the biological hypothesis. Bispecific small molecules passing all these quality gates may progress to full candidate delivery projects for Sanofi.

Rapid delivery of multiple bispecific opportunities will be empowered by a pipeline of Exscientia capabilities driven by Artificial Intelligence and enabled automated design.

 

Access your FREE copy

 


Biomarkers aren’t just supporting drug discovery – they’re driving it

FREE market report

From smarter trials to faster insights, this report unpacks the science, strategy and real-world impact behind the next generation of precision therapies.

What you’ll unlock:

  • How biomarkers are guiding dose selection and early efficacy decisions in complex trials
  • Why multi-omics, liquid biopsy and digital tools are redefining the discovery process
  • What makes lab data regulatory-ready and why alignment matters from day one

Explore how biomarkers are shaping early drug development

Access the full report – it’s free!

 

As part of this agreement, Exscientia will be responsible for all compound design, whilst chemistry synthesis will be delivered by Sanofi. Further assays, preclinical experiments and subsequent trials for compounds progressing to the clinic will be managed by Sanofi, where Sanofi exercises the licence option.

The commercial terms for this agreement include the payment of research funding in order to identify those target pairs with the best combination of chemical compatibility and strong biological relevance plus further funding for prioritised candidate delivery opportunities. For compounds reaching agreed delivery criteria, a series of milestones covering both non-clinical and clinical may be payable by Sanofi. Finally, any licensed products reaching the market will qualify for recurrent sales milestones. The total amount potentially payable by Sanofi to Exscientia on achieving these milestones is EUR250 million.

 

*Many effective drugs act via modulation of multiple proteins rather than single targets. Advances in systems biology are revealing a phenotypic robustness and a network structure that strongly suggests bispecific compounds could deliver superior clinical efficacy.

Related conditions

Related organisations
,

Leave a Reply

Your email address will not be published. Required fields are marked *